EVAH concludes Acquisition and Development Agreements for Four Technologies from Elanco

EVAH Corp. recently announced the signing of four contracts with Elanco Animal Health Incorporated to acquire and develop technologies in animal health. 

EVAH is a canadian biotechnology company specializing in the development of biologicals to help prevent bacterial diseases in food animals and microbiome solutions for growth performance.

The four contracts between EVAH and Elanco relate to four products in development (two feed additives and two vaccines) targeting three species: salmon, swine and poultry. EVAH intends to develop the products up to an advanced pre-commercial stage and consult with Elanco throughout the process. Terms of the deal remain confidential but do not involve an equity investment in EVAH from Elanco.

The collaboration between EVAH and Elanco originates from the long-standing relationship between the two groups. EVAH's management and scientific resources are teaming up again, having previously worked together at Prevtec Microbia. The Company has office and lab facilities in Québec (Montréal, Saint-Hyacinthe and Laval) and Prince Edward Island.

Elanco is an American pharmaceutical company listed on the New York Stock Exchange and a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole.

BCF is proud to have represented EVAH in this transaction, with a team composed of Mario Charpentier, Mireille Fontaine and Valérie Charpentier.

To read the press release, click here.